OakChart

Pacira BioSciences Inc

PCRXHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 3:48 PM ET

36.47-0.03 (-0.07%)
2026-11-11 21:49 CET
Market cap
1,463.06 USD m
Revenue, TTM
743.30 USD m
Net income, TTM
37.73 USD m
Free cash flow, TTM
169.00 USD m
EPS diluted, TTM
0.92
P/E
39.49
Compare

Price

PCRX against its 20, 50 and 200-day averages
2050200miss
25.0030.0035.0014.4M28.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PCRXclose 36.4720-day 36.3950-day 30.79200-day 25.4936.47

0.5% under the 52-week high of 36.67 on 15 Oct 2026. 52-week low 18.80 on 20 Jan 2026. Last 15 sessions, 0.5% high to low

Volume 0.32× normal · the line is the 50-bar volume average

Profile

PCRX
52-week range, 99% of the way up
18.8036.67

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Brisbane, CA.

IndexRUT
Employees829
IPOFeb 03, 2011
Beta0.22
ATR, 14d0.32
Rel volume0.32
Short float8.68%
Insider own3.75%
Inst own107.06%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.46B
Enterprise Value1.51B
Income37.73M
Sales743.30M
Book/sh17.85
Cash/sh7.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees829
IPOFeb 03, 2011

Ratios

P/E39.49
Forward P/E10.39
PEG0.52
P/S1.97
P/B2.04
P/C4.95
P/FCF8.65
EV/EBITDA13.19
EV/Sales2.03
Quick Ratio3.65
Current Ratio4.68
Debt/Eq0.48
LT Debt/Eq0.46
Option/ShortYes / Yes

Earnings

EPS (ttm)0.92
EPS next Y3.51
EPS next Q0.75
EPS this Y9.40%
EPS next Y21.07%
EPS next 5Y19.99%
EPS past 3/5Y-22.97% -45.77%
Sales past 3/5Y2.89% 11.07%
EPS Y/Y TTM101.62%
Sales Y/Y TTM3.70%
EPS Q/Q471.60%
Sales Q/Q-1.59%
EarningsAug 04 AMC
EPS/Sales Surpr.12.95% 0.70%

Ownership

Insider Own3.75%
Insider Trans-1.66%
Inst Own107.06%
Inst Trans-8.33%
ROA3.02%
ROE5.24%
ROIC3.62%
Gross Margin71.29%
Oper. Margin4.17%
Profit Margin5.08%
SMA200.19%
SMA5018.41%
SMA20043.04%
Trades-

Technical

Shs Outstand39.90M
Shs Float38.59M
Short Float8.68%
Short Ratio2.64
Short Interest3.35M
52W High36.67 -0.55%
52W Low18.80 93.96%
Volatility0.13% 0.21%
ATR (14)0.32
RSI (14)82.85
Beta0.22
Rel Volume0.32
Avg Volume1.27M
Volume389,967

Performance

Perf Week0.18%
Perf Month0.43%
Perf Quarter57.31%
Perf Half Y58.27%
Perf YTD40.90%
Perf Year51.18%
Perf 3Y28.04%
Perf 5Y-35.81%
Perf 10Y-0.91%
Recom3.00
Target Price34.79
Prev Close36.49
Price36.47
Change %-0.07%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 23, 2026InitiatedOOppenheimerOutperform$32-12.2%
Sep 09, 2026InitiatedLLeerink PartnersMarket Perform$28-23.2%
Aug 17, 2026ResumedTTruistBuy$30-17.7%
Dec 09, 2025InitiatedBBarclaysEqual Weight$27-26.0%
Nov 17, 2025InitiatedHH.C. WainwrightBuy
Jul 25, 2025UpgradeTTruistHold → Buy$30-17.7%
Jan 30, 2025UpgradeTTruistSell → Hold$8 → $25-31.4%
Aug 13, 2024DowngradeTTruistBuy → Sell$30 → $8-78.1%
Aug 12, 2024DowngradeRRBC Capital MktsOutperform → Sector Perform$37 → $14-61.6%
Aug 12, 2024DowngradeRRaymond JamesOutperform → Mkt Perform

Peers

Mkt cap
TickerCompanyMkt cap
HRTXHeron Therapeutics Inc68.04M
COLLCollegium Pharmaceutical Inc767.57M
ANIKAnika Therapeutics Inc185.54M
INDVIndivior Pharmaceuticals Inc5.97B
BVSBioventus Inc927.72M
AMPHAmphastar Pharmaceuticals Inc1.22B
AMRXAmneal Pharmaceuticals Inc7.61B
TLPHTalphera Inc54.50M
VRTXVertex Pharmaceuticals Inc138.81B
BAXBaxter International Inc13.69B

Insider trading

latest 14 of 40
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RIKER LAURENSenior Vice President, FinanceOct 08 '26Option Exercise32.356,000194,10068,284Oct 09 07:07 PM
RIKER LAURENSenior Vice President, FinanceOct 08 '26Sale36.326,000217,92062,284Oct 09 07:07 PM
RIKER LAURENOfficerOct 08 '26Proposed Sale36.326,000217,920Oct 08 10:02 AM
SLONIN JONATHANChief Medical OfficerAug 17 '26Sale23.233,04070,619216,384Aug 18 05:21 PM
SLONIN JONATHANOfficerAug 17 '26Proposed Sale23.233,04070,619Aug 17 11:54 AM
RIKER LAURENSenior Vice President, FinanceJun 11 '26Sale23.506,115143,70262,284Jun 12 09:07 PM
Ceesay AbrahamDirectorJun 12 '26Proposed Sale23.279,039210,374Jun 12 12:15 PM
RIKER LAURENOfficerJun 11 '26Proposed Sale23.506,115143,702Jun 11 11:28 AM
WILLIAMS KRISTENChief Administrative OfficerJun 04 '26Sale22.2710,259228,468167,062Jun 05 05:57 PM
WILLIAMS KRISTENOfficerJun 04 '26Proposed Sale22.2710,259228,468Jun 04 09:48 AM
Cross ShawnChief Financial OfficerApr 23 '26Option Exercise16.4512,941212,879118,282Apr 24 08:41 PM
Cross ShawnChief Financial OfficerApr 23 '26Sale25.1612,941325,596105,341Apr 24 08:41 PM
Cross ShawnOfficerApr 23 '26Proposed Sale25.1612,941325,576Apr 23 04:41 PM
Cross ShawnChief Financial OfficerApr 20 '26Option Exercise16.457,714126,895113,055Apr 22 08:03 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
IWMiShares Russell 2000 Index FundAUM: 77.38B
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-040.7300.6460.120192.4191.066
2026Q12026-04-300.6000.5480.071177.38171.87
2025Q42026-02-260.5700.9050.038196.87200.337
2025Q32025-11-060.7000.6780.122179.52181.116
2025Q22025-08-050.7400.710-0.107181.1183.076
2025Q12025-05-080.6200.5970.103168.92176.037
2024Q42025-02-270.9100.8350.327187.25184.78
2024Q32024-11-060.7900.705-3.110168.57169.559
2024Q22024-07-300.8900.6990.389178173.79
2024Q12024-05-070.6200.6200.192167.12165.329
2023Q42024-02-290.8900.8830.478181.24180.628
2023Q32023-11-020.7200.7810.228163.93172.958
2023Q22023-08-020.7800.7590.495169.47174.858
2023Q12023-05-030.5300.617-0.425160.34159.198
2022Q42023-02-280.8000.830-0.220171.96171.949
2022Q32022-11-030.6400.767-0.015167.47168.3311

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.6701.554-0.265421.03419.9
2020FY2.2102.1433.331429.65430.43
2021FY3.0002.9130.920541.53536.73
2022FY2.5902.6340.342666.82666.8
2023FY2.8102.9070.807674.98674.23
2024FY3.2003.150-2.153700.97698.86
2025FY2.6502.9550.160726.41729.87
2026FY-2.899--753.4
2027FY-3.510--789.98
2028FY-4.578--883.38
2029FY-4.527--866.38
2030FY-4.220--836.39

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-05801181.94176.7187.44
2026Q3S2026-10-21800182.87176.88187.44
2026Q3S2026-10-19801182.87176.88187.44
2026Q3S2026-10-08805182.87176.88187.44
2026Q3S2026-10-07805182.86176.88187.44
2026Q3S2026-10-02805183.04176.88188.85
2026Q3S2026-09-22805183.04176.88188.85
2026Q3S2026-09-08705182.21176.88186.8
2026Q3S2026-08-14605181.76176.88186.8
2026Q3S2026-08-07505182.73178.76186.8
2026Q3S2026-08-05504184.13178.76191
2026Q3S2026-08-04500190.61188.77192.47
2026Q3S2026-07-29500190.61188.77192.47
2026Q3S2026-07-17501190.61188.77192.47

Estimate history

EPS, annual-1.07-0.012-0.2653.3310.920.3420.807-2.1530.1560.9234
Period201720182019202020212022202320242025TTM
EPS, quarterly-3.110.3270.103-0.1070.1220.0380.0710.1160.699
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual286.63337.277421.026429.647541.533666.823674.978700.966726.411743.3
Period201720182019202020212022202320242025TTM
Sales, quarterly168.573187.253168.923181.099179.516196.873177.376192.399176.653
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual40.66941.22341.90843.63744.73445.92846.48146.24141.11739.897
Period201720182019202020212022202320242025MRQ
Shares, quarterly46.14846.24146.28344.89842.96641.11739.3139.82239.897
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue743.30726.41700.97674.98666.82541.53429.65421.03337.28
Cost of Goods Sold Incl. D&A213.43207.04227.72241.96256.58153.81125.19112.4286.84
Gross Profit529.87519.37473.25433.02410.24387.73304.45308.61250.43
Selling, General and Administrative Excl. Other498.85491.27375.68345.70339.31254.89252.94272.90225.85
Research and Development122.45117.3181.5876.2684.8055.5559.4272.1255.69
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income31.0228.1097.5787.3270.93132.8451.5235.7124.58
Interest Expense14.1417.4516.5720.3139.9831.7525.6723.6321.95
Unusual Expense-4.769.89163.4316.5710.9042.9117.3430.938.66
Net Income Before Taxes36.9416.87-63.1161.7013.3056.4020.09-10.75-0.42
Income Taxes-0.799.8436.4519.75-2.6114.42-125.430.270.05
Consolidated Net Income37.737.03-99.5641.9515.9141.98145.52-11.02-0.47
Net Income From Continuing Operations37.737.03-99.5641.9515.9141.98145.52-11.02-0.47
Net Income37.737.03-99.5641.9515.9141.98145.52-11.02-0.47
EPS (Recurring)0.840.310.321.030.511.583.610.260.14
EPS (Basic, Before Extraordinaries)0.940.16-2.150.910.350.953.41-0.27-0.01
EPS (Diluted)0.920.16-2.150.810.340.923.33-0.27-0.01
EBITDA114.26119.13176.36162.90162.43161.3871.4255.2937.74
Non-Operating Income (Expense)15.2616.1119.3211.26-6.75-1.7711.588.105.61
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense42.5245.4340.4337.8437.9942.2529.1424.5625.06
Price To Earnings Ratio39.5239.52-433.1297.6065.5818.23--
Price To Sales Ratio1.381.601.242.602.695.076.084.475.22
Gross Margin71.2971.5067.5164.1561.5271.6070.8673.3074.25
Operating Margin4.173.8713.9212.9410.6424.5311.998.487.29
Net Margin5.080.97-14.206.222.397.7533.87-2.62-0.14
Shares Outstanding39.9041.1246.2446.4845.9344.7343.6441.9141.22
Market Capitalization1,463.061,463.06869.901,566.811,771.512,680.242,599.671,890.411,768.72

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue176.65192.40177.38196.87179.52181.10168.92187.25
Cost of Goods Sold Incl. D&A49.5958.4950.7354.6248.6055.1948.6354.21
Gross Profit127.06133.91126.64142.25130.92125.91120.30133.04
Selling, General and Administrative Excl. Other110.52122.05127.22139.06117.76116.78117.32103.51
Research and Development26.6830.2428.0737.4525.9728.2025.3423.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income16.5411.86-0.573.1913.159.132.9829.53
Interest Expense2.883.623.703.894.284.704.584.68
Unusual Expense-5.737.59-7.480.857.770.630.994.83
Net Income Before Taxes28.812.565.000.579.52-1.938.7125.53
Income Taxes0.29-2.102.08-1.074.092.923.899.48
Consolidated Net Income28.524.652.921.645.43-4.854.8116.04
Net Income From Continuing Operations28.524.652.921.645.43-4.854.8116.04
Net Income28.524.652.921.645.43-4.854.8116.04
EPS (Recurring)0.600.25-0.060.050.24-0.100.120.40
EPS (Basic, Before Extraordinaries)0.720.120.070.040.12-0.110.100.35
EPS (Diluted)0.700.120.070.040.12-0.110.100.33
EBITDA35.8133.1620.7624.5334.3436.4524.1450.78
Non-Operating Income (Expense)9.431.911.792.128.42-5.7311.305.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.3411.8210.7010.6611.0412.2211.509.69
Price To Earnings Ratio39.52203.12143.8658.01----
Price To Sales Ratio1.381.371.261.531.601.541.651.32
Gross Margin71.9369.6071.4072.2672.9369.5371.2171.05
Operating Margin9.366.16-0.321.627.335.041.7615.77
Net Margin16.152.421.640.833.03-2.682.858.57
Shares Outstanding39.9039.8239.3141.1242.9744.9046.2846.24
Market Capitalization1,463.06997.93915.071,113.391,157.921,106.681,149.96869.90

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments238.42484.62278.58288.65656.41521.66291.95383.45311.35
Short Term Receivables124.37113.80105.5698.4096.3253.0547.5338.0031.66
Inventories152.86125.28104.3596.0698.5564.6558.3048.5741.41
Other Current Assets32.3221.4321.5015.2214.7712.2710.787.956.69
Total Current Assets547.97745.13509.99498.33866.05651.62408.56477.97391.11
Net Property, Plant & Equipment182.47216.39234.95254.39264.81211.18142.81108.67107.05
Total Investments and Advances0.000.002.4137.210.0095.4664.8040.0274.19
Intangible Assets388.31425.97646.50703.79769.14196.07203.9362.0455.20
Deferred Tax Assets123.85130.38144.49160.31153.36106.16---
Other Assets22.3135.6536.0527.1721.9914.0210.970.660.82
Total Assets1,264.921,553.521,574.391,681.202,075.351,274.51831.07689.35628.37
Short Term Debt Incl. Current Port. of LT Debt9.84210.6617.4442.77382.59157.074.930.340.32
Accounts Payable15.1519.1315.7015.2210.5410.4312.8014.3714.66
Income Tax Payable---0.000.430.111.330.090.08
Other Current Liabilities95.6080.1264.2489.78127.5685.7188.6145.8741.16
Total Current Liabilities120.59309.9297.38147.77521.12253.33107.6760.6656.22
Long Term Debt408.37428.19568.60720.62746.26384.06346.98290.59276.17
Provision for Risks Charges3.904.204.303.302.402.002.502.201.50
Deferred Tax Liabilities4.21--------
Other Liabilities34.7432.8633.9734.4975.1715.4418.9614.6715.00
Total Liabilities571.81775.17704.26906.191,344.94654.83476.12368.13348.89
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity693.11778.35870.13775.01730.41619.69354.94321.23279.48
Total Shareholders Equity693.11778.35870.13775.01730.41619.69354.94321.23279.48
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity693.11778.35870.13775.01730.41619.69354.94321.23279.48
Total Liabilities & Stockholders Equity1,264.921,553.521,574.391,681.202,075.351,274.51831.07689.35628.37
Book Value Per Share16.8616.8318.7216.8716.3314.208.477.796.87
Tangible Book Value Per Share7.417.624.811.55-0.879.713.606.295.51
Full-Time Employees829790712715697624606518489
Price to Book Ratio2.041.161.882.303.694.215.355.526.99
Return on Assets0.50-6.372.580.852.5113.82-1.45-0.07-8.36
Return on Equity0.96-12.085.102.116.2229.86-3.26-0.16-17.10
Return on Invested Capital0.64-8.252.921.062.8414.50-1.57-0.08-7.67
Quick Ratio3.282.004.172.721.472.323.257.086.22
Current Ratio4.542.405.243.371.662.573.797.886.96

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income37.737.03-99.5641.9515.9141.98145.52-11.02-0.47
Depreciation83.2491.0278.7875.5791.5028.5519.9119.5813.16
Other Funds (Non Cash)23.3385.73208.0667.2862.2469.8372.0171.1047.03
Funds from Operations145.48190.26207.91200.43161.71151.23110.8379.6659.73
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital31.42-38.27-18.52-45.78-16.43-25.51-33.80-9.14-10.86
Cash from Operating Activities176.90151.99189.39154.65145.27125.7277.0370.5248.87
Capital Expenditures-7.90-15.33-10.64-15.16-30.08-45.87-37.80-10.16-14.51
Net Assets From Acquisitions-6.33-16.700.000.000.00-420.040.00-117.69-
Sale of Fixed Assets and Businesses73.560.000.000.000.000.000.000.00-
Purchase or Sale of Investments52.02131.52-72.6492.70-163.11449.12-239.81-0.6441.93
Purchase of Investments-58.67-142.29-252.21-144.37-400.69-628.67-547.68-320.11-363.25
Sale Or Maturity of Investments110.69273.81179.57237.07237.581,077.79307.87319.47405.19
Other Uses0.000.000.000.00-32.00-4.000.000.00-6.84
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities111.3499.48-83.2877.54-225.19-20.79-277.61-128.4920.58
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-94.02-145.03-22.704.7527.3426.6647.7610.878.95
Repurchase of Common Pref Stock-98.29-148.33-25.000.000.000.000.000.000.00
Sale of Common Pref Stock4.283.302.304.7527.3426.6647.7610.878.95
Proceedsfrom Stock Options2.952.802.302.812.952.810.000.000.00
Issuance or Reduction of Debt, Net-84.98-218.9940.56-187.68-427.69359.20180.13-0.570.00
Change in Long Term Debt-84.98-218.9940.56-187.68-270.73359.20180.13-0.570.00
Issuance of Long Term Debt0.0298.81278.15142.640.00359.20390.010.000.00
Reduction of Long Term Debt-85.00-317.80-237.59-330.31-270.730.00-209.88-0.570.00
Net Financing Active Other Cash Flow-9.47-5.62-0.49-0.110.00-5.17-5.59-6.630.00
Other Financing Activities Uses-9.47-5.62-0.49-0.110.00-5.17-5.59-6.630.00
Cash from Financing Activities-188.47-369.6317.36-183.03-401.53380.69222.303.678.95
Exchange Rate Effect-0.41-0.08-------
Net Change in Cash99.37-118.23123.4849.16-481.44485.6221.73-54.3078.40
Free Cash Flow169.00136.66178.75139.49115.2079.8539.2360.3634.36
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow6.058.534.8712.5715.6034.3866.6331.1551.23
Deferred Taxes & Investment Tax Credit-6.4820.6215.62-7.9510.87-126.610.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments295.58251.03202.18238.42246.33445.86
Short Term Receivables122.89132.62125.73124.37115.47114.77
Inventories129.49134.57150.37152.86157.68148.16
Other Current Assets42.2696.9936.6832.3243.2736.82
Total Current Assets590.23615.22514.96547.97562.75745.61
Net Property, Plant & Equipment171.63175.20175.69182.47191.65201.71
Total Investments and Advances7.757.750.000.000.000.00
Intangible Assets292.54305.13373.00388.31402.71442.86
Deferred Tax Assets125.31124.60122.11123.85120.19128.27
Other Assets12.6913.5922.7722.3120.2718.81
Total Assets1,202.641,243.981,208.531,264.921,297.581,537.26
Short Term Debt Incl. Current Port. of LT Debt10.0910.309.829.849.75212.02
Accounts Payable17.5017.5114.0115.1517.6930.12
Income Tax Payable1.900.100.00-0.600.90
Other Current Liabilities96.6094.1084.9695.6079.0470.12
Total Current Liabilities126.10122.01108.79120.59107.08313.16
Long Term Debt330.19401.82401.36408.37415.56419.39
Provision for Risks Charges0.000.000.003.900.004.20
Deferred Tax Liabilities4.034.074.094.214.594.58
Other Liabilities30.0044.1040.4034.7443.1438.16
Total Liabilities490.32572.00554.64571.81570.36779.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity712.32671.98653.89693.11727.21757.77
Total Shareholders Equity712.32671.98653.89693.11727.21757.77
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity712.32671.98653.89693.11727.21757.77
Total Liabilities & Stockholders Equity1,202.641,243.981,208.531,264.921,297.581,537.26
Book Value Per Share17.8516.8716.6316.8616.9316.88
Tangible Book Value Per Share10.529.217.157.417.557.01
Full-Time Employees---829--
Price to Book Ratio2.041.531.341.531.531.39
Return on Assets3.021.050.370.501.52-8.01
Return on Equity5.242.050.710.962.90-15.57
Return on Invested Capital2.740.430.280.150.48-0.41
Quick Ratio3.653.943.353.283.781.91
Current Ratio4.685.044.734.545.262.38

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income28.524.652.921.645.43-4.85
Depreciation18.6121.9621.3321.3421.1927.32
Other Funds (Non Cash)-8.1310.4411.279.7542.1326.99
Funds from Operations38.2840.9737.2528.9876.8350.21
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital11.7916.49-11.5714.71-15.99-38.20
Cash from Operating Activities50.0757.4625.6843.6960.8312.01
Capital Expenditures-3.62-1.34-2.72-0.22-3.87-2.70
Net Assets From Acquisitions-6.000.00-0.340.000.000.00
Sale of Fixed Assets and Businesses73.560.000.000.000.000.00
Purchase or Sale of Investments-3.1213.1022.5019.5547.4864.86
Purchase of Investments-27.17-3.900.00-27.59-38.77-6.31
Sale Or Maturity of Investments24.0517.0022.5047.1486.2571.17
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities60.8111.7619.4419.3343.6162.16
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.382.18-50.04-46.53-50.03-48.47
Repurchase of Common Pref Stock0.000.00-50.05-48.25-50.04-50.04
Sale of Common Pref Stock0.382.180.001.720.011.57
Proceedsfrom Stock Options0.001.720.001.230.001.57
Issuance or Reduction of Debt, Net-70.00-5.00-5.00-4.98-207.44-3.75
Change in Long Term Debt-70.00-5.00-5.00-4.98-207.44-3.75
Issuance of Long Term Debt0.000.000.000.0298.800.00
Reduction of Long Term Debt-70.00-5.00-5.00-5.00-306.24-3.75
Net Financing Active Other Cash Flow-0.14-4.83-4.36-0.14-0.01-5.29
Other Financing Activities Uses-0.14-4.83-4.36-0.14-0.01-5.29
Cash from Financing Activities-69.77-7.65-59.40-51.65-257.48-57.51
Exchange Rate Effect-0.030.000.04-0.41--
Net Change in Cash41.0861.57-14.2410.96-152.9016.87
Free Cash Flow46.4556.1222.9643.4756.969.31
Price to Free Cash Flow6.055.706.978.149.229.28

Revenue breakdown

Product2024: 697.19M 2025: 722.85M
Royalty2024: 3.78M 2025: 3.56M
United States2024: 700.97M 2025: 726.41M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.68%3.3M38.6M1.24M
2026-10-1511.10%4.3M38.4M1.19M
2026-09-3021.15%8.1M38.2M576.08K
2026-09-1519.80%7.6M38.2M582.69K
2026-08-3119.19%7.3M38.2M546.95K
2026-08-1419.11%7.3M38.2M553.99K
2026-07-3118.89%7.2M38.2M522.25K
2026-07-1518.48%7.0M37.7M522.53K
2026-06-3017.48%6.6M37.7M528.98K
2026-06-1516.67%6.3M37.7M571.66K
2026-05-2917.48%6.6M37.7M649.15K
2026-05-1518.51%7.0M37.7M720.66K
2026-04-3020.65%7.8M37.7M724.59K
2026-04-1519.03%7.4M38.8M792.98K
2026-03-3120.78%8.1M38.8M908.40K
2026-03-1321.79%8.4M38.8M917.21K
2026-02-2721.85%8.5M38.8M901.67K
2026-02-1318.65%7.7M41.2M861.92K
2026-01-3018.90%7.9M41.7M899.51K
2026-01-1517.10%7.1M41.6M826.49K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5021.8026.1023.957.4002.000.000.993-0.0220.001
call15.0019.3023.600.006.2920.000.000.991-0.0220.001
call17.5016.8021.100.005.3870.000.000.990-0.0210.002
call20.0014.4018.6016.254.6189.000.000.987-0.0210.002
call22.5011.9016.100.003.9450.000.000.985-0.0210.002
call25.009.4013.602.303.3414.000.000.981-0.0200.003
call27.506.9010.509.402.39129.000.000.977-0.0200.003
call30.005.007.906.431.85276.000.000.969-0.0190.004
call32.502.006.001.551.7126.000.000.954-0.0170.005
call35.001.451.650.900.2854.000.000.885-0.0180.011
call37.500.000.050.050.1374180.000.173-0.0140.015
call40.000.000.050.040.3465.000.000.074-0.0160.008
call42.500.002.150.000.5390.000.000.041-0.0150.005
call45.000.002.150.000.6980.000.000.033-0.0160.004
call47.500.002.150.000.8430.000.000.028-0.0170.004
call50.000.002.150.000.9750.000.000.025-0.0180.003
put12.500.000.050.032.97716.000.00-0.007-0.0180.001
put15.000.000.050.402.50289.000.00-0.009-0.0180.001
put17.500.000.050.652.1952.000.00-0.010-0.0190.002
put20.000.000.051.801.8301.000.00-0.013-0.0190.002
put22.500.002.150.001.4960.000.00-0.015-0.0180.002
put25.000.000.053.001.16310.000.00-0.019-0.0160.003
put27.500.000.053.500.9455.000.00-0.023-0.0170.003
put30.000.001.050.060.6642.000.00-0.031-0.0140.004
put32.500.000.050.050.4322.000.00-0.046-0.0120.006
put35.000.000.050.050.1971,5750.00-0.267-0.0440.020
put37.500.001.151.090.21911.000.00-0.836-0.0100.014
put40.001.405.703.801.5595.000.00-0.929-0.0130.008
put42.503.908.200.001.8690.000.00-0.959-0.0100.005
put45.006.4010.700.002.1450.000.00-0.967-0.0110.004
put47.508.9013.200.002.3920.000.00-0.972-0.0120.004
put50.0011.4015.700.002.6150.000.00-0.975-0.0120.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-03SC 14D9/ASEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-30SC 14D9Tender offer solicitation / recommendation statements filed under Rule 14-d9SEC
2026-10-30SC TO-TThird party tender offer statementSEC
2026-10-13SCHEDULE 13D/ASEC
2026-10-094Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-08144Filing for proposed sale of securities under Rule 144.SEC
2026-10-08SC TO-CWritten communication relating to an issuer or third party tender offerSEC
2026-10-08SC TO-CWritten communication relating to an issuer or third party tender offerSEC
2026-10-08SC14D9CWritten communication by the subject company relating to a third party tender offerSEC
2026-10-088-KCurrent report2026-10-08SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13GSEC
2026-08-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-06-308-KCurrent report2026-06-28SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000217.92K1
2026-090000
2026-080070.62K1
2026-070000
2026-0600372.17K2
2026-050000
2026-0400628.19K4
2026-030085.32K2
2026-0200352.94K2
2026-010034.32K1
2025-1200626.75K2
2025-1100361.80K2

Institutional holders

Manager% owned
ABSOLUTE INVESTMENT ADVISERS, LLC28.85%
BlackRock, Inc.17.05%
Doma Perpetual Capital Management LLC7.06%
VANGUARD PORTFOLIO MANAGEMENT LLC6.12%
DIMENSIONAL FUND ADVISORS LP5.70%
STATE STREET CORP5.24%
D. E. Shaw & Co., Inc.4.96%
RENAISSANCE TECHNOLOGIES LLC4.41%
VANGUARD CAPITAL MANAGEMENT LLC4.30%
GOLDMAN SACHS GROUP INC3.88%

Funds

Fund% owned
iShares Convertible Bond ETF15.13%
American Beacon SSI Alternative Income Fund9.66%
iShares Core S&P Small-Cap ETF6.03%
Fidelity Convertible Securities Fund5.22%
Miller Intermediate Bond Fund4.94%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.05%
iShares Russell 2000 ETF2.63%
ABSOLUTE FLEXIBLE FUND2.54%
VANGUARD SMALL-CAP INDEX FUND2.18%
Strategic Alternatives Fund2.04%

OakChart. PCRX. Cached 15 minutes.